Risedronate is a pyridinyl bisphosphonate. It is licensed for prevention and treatment of both postmenopausal and corticosteroid-induced osteoporosis at a recommended dose of 5mg daily.
The overall incidence of adverse effects in trials with risedronate is similar to placebo, even for upper GI events. Patients with active GI disease or on NSAIDs were not excluded from these trials.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.